Discover All Perspectives.

Published 2 years ago • loading... • Updated 2 years ago

Corcept Therapeutics plunges amid patent trial with Teva (NASDAQ:CORT)

Summary by Ground News

Corcept (CORT) has been in a patent battle with Teva (TEVA) over a patent for Cushing’s syndrome drug Korlym, marketed by Corcept. Corcept originally sued Teva in federal court in March 2018 to prevent it from marketing a generic version of KorlyM.

1 Articles

1 Articles

All

Left

Center

Right

1

Corcept Therapeutics plunges amid patent trial with Teva (NASDAQ:CORT)

Corcept Therapeutics faces a potential setback as it engages in a patent trial with Teva Pharmaceuticals, causing its shares to decline by 18%.

2 years ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right1Center0Last Updated2 years agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States 2 years ago on Friday, September 29, 2023.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics